ALZHEIMER'S disease (AD), is marked by cortical dementia, memory loss, personality changes, and signs of cortical disconnection (2) . The characteristic neuropathology of AD is the abundance of neurofibriUary tangles (NFT's) and amyloid-containing neuritic plaques (NP's) in the cerebral cortex and hippocampus (29) . NFr's represent the accumulation of abnormal paired helical filaments in the cytoplasm of neurons, whereas NP's are comprised of dystrophic neurites and glial processes, with or without an amyloid core (68) . In the cerebral cortex, NFT's are found primarily in pyramidal neurons and both NFF's and NP's are thought to be more common in association cortex than in the primary sensory regions (for reviews see 4, 5, 28, 53, 55, 66) . In addition to the accumulation of NFT's, the large pyramidal cells of the cerebral cortex become significantly depleted in AD (36, 67) . In a study by Lewis et al (34) , the regional and laminar distribution of NFF's were found to be strikingly similar to the known distribution of corticocortical pyramidal neurons in the visual cortex of AD brains, whereas NP's had a less specific regional and laminar distribution (4, 5) . Pyramidal neurons (found mainly in layers III and V) furnish the long corticocortical projections re-1 To whom requests for reprints should be addressed. 343 quired for the intricate connections between appropriate areas of cerebral cortex. It is thought that the dementia of AD results from the degeneration of these long corticocortical projection neurons and the loss of the connections they furnish (49) . It was also determined in the study of Lewis et al. (34) that the number of NFT's was very low in primary striate cortex (primary visual, Area 17 but increased 20-fold in the immediately adjacent visual association cortex (secondary visual, Area 18), and showed a further doubling in the next higher-order visual association cortex (tertiary visual, Areas 19, 20, 21) . Thus, the number of NFr's progressively increased across primary, association, and higherorder association visual cortex in a manner which parallels their position in the proposed hierarchical organization of the visual cortex (70, 71) . This hierarchical pattern of increasing NFT vulnerability within successive areas of the cerebral cortices appears to be correlated with the hierarchies of corticocortical connections (4, 15) .
Excitatory amino acids (EAA's) are thought to be the principal excitatory neurotransmitters of cortical neurons (9, 11, 14, 16, 19, 23, 64, 69) . Abundant evidence from neurochemical, electrophys-iological, immunocytochemical, and transport studies indicate that the pyramidal neurons comprising corticocortical association, corticofugal, and some intracortical projections utilize glutamate as their primary EAA neurotransmitter (for a review see ref. 69 ). In addition, the EAA receptors of some of these cortical pathways have been characterized (1, 23, 26, 44, 58, 69) .
Recent interest has focused on the potential role of EAA's in AD and the pathologic role of EAA's as excitotoxins has received a tremendous amount of attention (for reviews see refs. 10, 17, 23, 31, 38, 39, 40, 51) . Several studies have shown that excitotoxins can induce the formation of abnormal cytoskeletal proteins, paired helical filaments (NFr's), and NP's resembling those seen in AD brains (3, 12, 31, 39, 40) . NFT's have been found in glutamate-immunoreactive neurons (32) .
The NMDA subtype of EAA receptor, by nature of its effects on calcium and its propensity to cause neurotoxicity, has been hypothesized to play a role in the neurodegeneration of AD (7, 23, 24, 31, 39, 40, 45, 54) . Furthermore, the glycine modulatory site of the NMDA receptor has been proposed as an attractive target for potential therapeutic regulation of EAA neurotransmission in AD (8, 57, 58, 59) . Glutamatergic denervation and possible abnormal metabolism in AD has recently been shown (56) . Selective reductions in EAA receptor levels in the cortex and hippocampus of AD also suggest a possible role for EAA neurotransmitters in the pathogenesis of the disease (13, 21, 22, 27, 37, 54, 57, 58, 59) .
In a recent study, specific laminar alterations in non-EAA receptors in AD cingulate cortex were found, suggesting that heterogeneities in cortical AD neuropathology are reflected in the laminar patterns of binding to postsynaptic receptors (72) . Anatomical studies indicate that the characteristic pathology of AD distributes in relation to EAA cortical association pathways (53, 60 
EXPERIMENTAL PROCEDURES

Tissue Preparation
Brains of 8 individuals who had died with AD and 8 nondemented controls were obtained at necropsy. AD pathology was defined according to previous neuropathologic criteria (29) . The postmortem delay and age at death were matched so that the control and AD brains were not significantly different; the average postmortem delay was 16 ---4 (SD) h for the controls (range 12-24 h) and 14 -+ 6 h for the AD cases (range 7-22 h). The average age at death was 72 -6 years for the controls (range 64-82 years) and 73 ---9 years for the AD brains (range 61-82 years). The brains were sectioned in a coronal plane, cut into slabs, frozen in crushed dry ice, placed in sealed plastic bags, and stored at -70°C. For this study, the slabs were brought from -70 ° to -20°C and blocks containing either occipital lobe containing the caicarine fissure, corresponding to primary and association visual cortex (Brodmann Areas 17 and 18), or posterior middle temporal gyrus, corresponding to higher-order visual association cortex (Brodmann Area 21), were cut by JBP and presented to the other investigators as coded samples. These blocks were coated with Lipshaw embedding matrix, placed in zip-lock plastic bags, and stored at -70°C until the time of the experiment. All binding assays and data analyses were completed before the code was broken and the statistical comparisons made.
On the day prior to assay, the blocks of occipital and temporal cortex were brought from -70 ° to -20°C by placement in a -20°C freezer overnight, mounted on cryotome chucks, and serial sections (20 microns thick) cut on a Lipshaw cryostat. The sections were then thaw-mounted onto twice gelatin-coated slides and stored at -20°C. All assays were performed within 2 days of sectioning. Additional sections were cut for cresyl violet and thioflavine S staining (see below). 
[3H]Glycine Binding Assay
The glycine modulatory site (strychnine-insensitive) of the NMDA-receptor complex was assayed using a modified version of the method used for rat brain by McDonald et a1. (43) . Briefly, sections were prewashed in 50 mM Tris-C1 buffer (pH 7.4) at 25°C for 30 min and then dried with cool air. The sections were then immersed in cytomailers containing 4°C Tris-C1 buffer, 100 nM [3H]glycine (Amersham, S~A. 19.9 Ci/mmol) and 1 mM strychnine (chloride salt). Preliminary experiments determined that these prewash and buffer conditions were optimal for a high ratio of specific to nonspecific [3H]glycine binding in the human tissue. Nonspecific binding was determined in the presence of 1 mM unlabelled glycine and represented less than 10% of total binding. After a 35-min incubation period at 4°C to allow binding to occur, the sections were rapidly rinsed four times with 4 ml each of 4°C Tris-Cl buffer only. The sections were then dried under a stream of cool air (total rinse time was less than 10 s). This rinse protocol was also determined to be optimal for specific [3H]glycine binding in the human brain tissue used for this study (laminated visual cortex). A similar method for assaying the strychnine-insensitive [3H]glycine binding site in human tissue autoradiographically has been reported (26, 27) .
Other Ligand Assays
The NMDA site of the NMDA-receptor complex was assayed as NMDA-sensitive [3H]glutamate binding in the presence of saturating amounts of quisqualate and kainate using a modification of the protocols of Greenamyre et al. (20) and Penney et al. (54) . Briefly, following a 30-min prewash at 4°C, sections were incubated in cytomailers (4°C) with 65 nM [3H]glutamate plus 2.5 mM quisqualate and 1 mM kainate in 50 mM Tris-acetate buffer (pH 7.4). 3-(2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP, 100 mM) was used to determine nonspecific binding. Sections were then rinsed four times with 4 ml each of 4°C Tris-acetate buffer, followed by two rinses of 2 ml each of 2.5% glutaraldehyde in acetone (4°C) and drying.
D,L-c~-amino-3 -hydroxy-5 -methyl-4-isoxazolepropionic acid ([3H]AMPA, 10 nM) was used to assay binding to the AMPA receptor in 50 mM Tris-C1 buffer containing 2.5 mM CaC12 and 30 mM KSCN (pH 7.2) essentially as described above for the NMDA receptor, using 1 mM L-glutamate to determine nonspe-cific binding (46, 50, 74) . All assays were run in triplicate for the totals and duplicate for the nonspecific binding.
[3H]Flunitrazepam (10 nM) was used to measure binding to the BDZ (benzodiazepine) receptor (54, 73) . Briefly, sections were washed in 50 mM Tris-citrate buffer (pH 7.0) three times for 5 min each at 4°C, dried under a stream of cool air and exposed to ligand buffer for 30 rain at 4°C. Following incubation the sections received one quick dip in buffer (4°C) followed by two 5 min rinses in buffer and a quick dry under hot air. Clonazepam (2 mM) was used to determine nonspecific binding.
Quantification of Receptor Binding
Upon completion of the assays, the slides were cut and taped onto sheets, apposed to tritium sensitive film (Amersham Hyperfilm) in sealed cassettes along with known radioactive standards (~4C) and exposed for 10 days to 4 weeks at -20°C. The films were developed in Kodak D-19 and binding levels were quantitated in each of the cortical areas with computer assisted densitometry using the MCID system (Imaging Research, Inc., St. Catharines; Ontario). Using this system, optical density values were converted to pmol/mg protein using a computer generated polynomial regression analysis which compared film densities produced by the tissue sections to those of the known radioactive standards (52) . Cresyl violet-stained adjacent sections (see below) were used as templates to delineate the six layers of each cortical area; multiple readings were taken and averaged in each layer of the overlaid autoradiograph using a variable size cursor. Cortical layers were classified according to the cytoarchitectonic scheme of Horton and Hedley-Whyte (25) . It was possible to delineate layers I from II, II from III, III from IV or IVb, IVb from IVc, IVc or IV from V, V from VI, and VI from subcortical white matter in the autoradiograms. Ligand binding in these layers was determined in three separate cortical areas: primary visual cortex (Brodmann Area 17), visual association cortex (Brodmann Area 18), and the higher-order visual association cortex (Brodmann Area 21). All data presented were analyzed densitometrically from the autoradiograms. The level of binding of each ligand in each layer of the three cortical areas of the control samples were compared to those in the AD samples using a student t test (unpaired, et = 0.05).
Histology
Cresyl violet staining histochemistry was carried out as follows. Sections adjacent to those used for autoradiography were fixed over paraformaldehyde vapor for a minimum of 48 h, stained with 0.5% cresyl violet, dehydrated in graded alcohols and xylene, and coverslips affixed with Permount (Fisher). Additional paraformaldehyde fixed sections were stained with 0.1% Thioflavine S for 13-amyloid protein. These sections were analyzed using a fluorescent microscope to count the number of NFrs and NPs (neuritic plaques) in the Alzheimer's sections. The number of NFTs and NPs in each layer of each area were compared by ANOVA with post hoc comparisons.
RESULTS
The number of senile plaques and neurofibrillary tangles in each layer of the different regions of the Alzheimer's brains are shown in Table 1 . There were significant differences [p < 0.0001; two-way analysis of variance (ANOVA)] in the number of plaques in the different layers but not in the different areas. The number of plaques in layers 3 and 5 was higher than in the other layers (p < 0.05 by Fischer PLSD). The number of tangles in layer 5 were significantly different in the different areas (p < 0.02 by ANOVA) with the higher-order association cortices having more tangles.
The laminar pattern of NMDA, AMPA, and BDZ binding clearly distinguished primary striate visual cortex (Brodmann Area 17) from the surrounding visual association cortex (Brodmann Area 18) and higher-order visual cortex (Brodmann Area 21). As others have reported (1, 26) in Area 17, layer IVb binding was very low due to tritium absorption by the white matter in the line of Gennari. This decrease in layer IV binding was much less evident in Areas 18 and 21. The other major difference between the ligands was in the higher synaptic density in layer IVc that is not present in Areas 18 and 21. The ligands differed greatly in their amount of binding to this layer. NMDA and glycine binding sites showed similar patterns of laminar densities whereas the patterns of these two binding sites were different from AMPA and BDZ binding by three-way ANOVA; AMPA and BDZ binding patterns were different also. The details of this binding and the differences between control and AD are given below.
[3H]Glycine Binding
Glycine binding to the NMDA receptor complex was found heterogeneously distributed across all laminae of each area of visual cortex examined. In the primary visual cortex (Brodmann Area 17, Figs. 1 and 2A) , glycine binding was highest in layer IVc, moderately high in layers II, III, and somewhat lower in layers I, IVb, V, and VI. In all six layers of the primary visual cortex, the [3H]glycine binding levels were slightly reduced in the AD brains; however, only in layer VI did the data reach statistical significance. In visual association cortex (Brodmann Area 18, Figs. 1 and 3A) , glycine binding was highest in layers II and III, and lower in layers I, IV, V, and VI. In this area of visual cortex, (26) . Furthermore, [3H]glutamate binding to the NMDA receptor complex in this study followed the same trend as glycine binding in the AD brains (i.e., the patterns of change of the two ligands were not significantly different by two-way ANOVA); that is, a progressive decrease in binding is seen in the AD brains in the visual association cortices, although the data did not reach statistical significance (Figs. 1, 2B, 3B, 4, and 5B).
NMDA-Sensitive [3H]Glutamate Binding
[3H]AMPA Binding
The laminar distribution of [3H]AMPA binding differed from that of the two NMDA receptor ligands.
[3H]AMPA binding was highest in layers II and III of primary visual cortex and relatively low in layer IVc (Figs. 1 and 2C) . In layer II of primary visual cortex, [3H]AMPA binding was significantly reduced (approximately 35%) in the AD brains, although binding in all laminae was slightly lower. In the visual association cortex (Figs. 1 and 3C ), [3H]AMPA binding remained highest in layers II and III but in the AD brains was significantly reduced in layers III, IV, V, and VI. In the higher-order visual association cortex, however, [3H]AMPA binding was not significantly altered in any layer of the AD brains (Figs. 4 and 5C) . Therefore, the laminar pattern of [3H]AMPA binding in the three areas of visual cortex studied differed from that of the NMDA receptor complex. This may reflect the different pattern of distribution or density of the two EAA receptor types in these cortical laminae.
[3H]Flunitrazepam Binding 
DISCUSSION
Summary of Results and Comparison With Other Studies
In this study, a hierarchical pattern of receptor binding vulnerability in AD was examined at successive levels of visual cortex. The hierarchical pattern was most obvious for [3H]glycine binding to the NMDA receptor, although a parallel trend was obtained for NMDA-sensitive VH]glutamate binding, where increasing reductions in laminar binding were found at each higher level of association cortex. The pattern of glycine binding loss paralleled the increase in AD neuropathology (NFT number) seen in primary, association, and higher-order association visual cortex (4, 34) . Binding to the AMPA receptor was reduced as well but only at the first level of visual association cortex (Brodmann Area 18), whereas the BDZ receptor binding pattern was reduced only in the highest-order level of visual association cortex (Brodmann Area 21).
The results obtained in our study for the laminar distribution of , although different cytoarchitectonic schemes were used in the two studies. The cytoarchitectonic scheme incorporated by Jansen et al. was developed for the macaque visual cortex (35) and includes both a layer IVa as well as a subdivision of layer 1Vc into IVca and IVcb. Thus, differences between our studies and that of Jansen et al. (26) lie in the assignment of cortical laminae. In our studies, we used the cytoarchitectonic scheme of Horton and Hedley-Whyte (25), which was developed for the human striate visual cortex and which does not include a layer IVa or the subdivision of layer IVc into a and b. In addition, our study further examines EAA receptor binding parameters at higher levels of visual association cortex and compares the control data to that of AD brains. Binding to the BDZ receptor was also included in our study, and our results were found to be comparable to those obtained by other groups for human primary visual cortex (61, 75) . Thus, the laminar distributions of EAA and BDZ receptors are quite distinctive in the human visual cortex, suggesting that the pattern of EAA and non-EAA neurotransmission may vary from layer to layer in each area of the visual hierarchy. The results provided in our study contribute additional information about which types of EAA receptors in the visual hierarchy are selectively vulnerable in AD.
Visual Cortex, AD Neuropathology, and Excitatory Amino Acids
The human visual system is a complicated array of networks interconnecting many levels of association cortices. Recent studies propose the existence of an elaborate hierarchical processing stream to explain the various connections of the association cortices of the visual system (15, 41, 70, 71) . Interestingly, a similar hierarchical pattern of neuropathology has recently been discovered in AD visual cortex (4, 34) . In these studies, NFI"s found in pyramidal neurons increase in number at each step of the hierarchy from primary visual cortex to higher levels of visual association cortices. There appears to be a pattern of selective vulnerability in the neuropathological pattern of cortical neurodegeneration in AD visual cortex as evidenced with the increasing numbers of NFT's. The findings from these studies may provide an anatomical basis for the loss of intellectual functions in AD and are consistent with the hypothesis that the dementia in AD results from the loss of the structural and functional integrity of the long corticocortical projection systems (34, 49, 53) .
Abundant evidence exists for the role of EAA's in the visual cortex (9, 26, 30, 42, 61) . These studies indicate that the pyramidal neurons comprising corticocortical association fibers, such as those found in the visual cortex, utilize glutamate as their primary EAA neurotransmitter. Although many investigators have demonstrated selective EAA receptor changes in AD in both cortex (22, 23, 57, 58, 59, 62, 72) and hippocampus (13, 21, 23, 27, 37, 54) , the results presented here provide the first comprehensive study of EAA receptor alterations in AD visual cortex. It is not known, however, at what point in the course of the disease that these alterations in EAA receptors become manifest. This is an important issue, for the fact that EAA receptor levels change with AD may only be a result of the neurodegenerative process and thus simply an effect of the disease, rather than an active cause. In future studies, an examination of the expression of the genes and proteins for EAA and GABA receptors is warranted to ascertain whether there may be a fundamental alteration in these receptors that precedes the overt pathology. These latter studies would have to be carded out in early AD cases or even in normal aging to determine the relationship of gene and protein expression to the progression of the disease.
The laminar pattern of EAA and BDZ receptor binding within the primary and association visual cortices probably results in a heterogeneous character of EAA mediated neurotransmission within the laminar hierarchy of the visual cortex. Autoradiographic studies of neurotransmitter receptors can provide novel information about the anatomical and functional organization of the visual cortex and may provide insight into the AD neuropathology also seen in those same areas of visual cortex. Anatomical studies have indicated that the characteristic pathology of AD is often associated with EAA cortical association pathways (53, 60) . In our study, AMPA receptor losses do not parallel the pathology, suggesting that AMPA receptors do not play a direct role in the AD pathology. The significant alterations in glycine binding to the NMDA receptor complex observed in our study, however, are intriguing because NMDA receptors have been implicated in synaptic plasticity in the primary visual cortex (5, 18) . In addition, it has been speculated that EAA receptors may play a role in the generation of AD neuropathology, by nature of their excitotoxic potential (3, 12, 23, 31, 39, 40, 51, 56) . Thus, EAA receptor sites may be exploited therapeutically in the design of future treatment for AD.
Modulatory Role of Glycine
In light of these interpretations, it is interesting that glycine, of the four ligands examined in our study, most directly reflected the hierarchical pattern of AD neuropathology. The changes in glycine binding were significant while those of NMDA were not. Note, however, that the addition of glycine to the incubation mixture enhances basal NMDA-sensitive glutamate binding (the so-called glycine-dependent NMDA receptor binding). We did not add glycine to the incubation media for the NMDA-sensitive glutamate binding assay. The addition of glycine to our glutamate assay may have resulted in a more significant decrease in NMDA receptor binding in the AD brains (57, 58, 59) . A decrease in glutamate binding to the NMDA receptor in AD may in fact represent a reduction in the glycine enhancement of glutamate binding (62) . Clearly, these modulatory interactions require further study. Nevertheless, these findings are provocative because of glycine's proposed role as a neuro-modulator (45) . It has been suggested that the glycine allosteric site of the NMDA receptor could be targeted therapeutically for the possible treatment of neurodegenerative disorders such as AD (8, 23, 24) . In response to this suggestion, recent reports have focused on glycine and found that its modulation of the NMDA receptor is in fact disrupted in AD (57, 58, 59, 62) . With the recent cloning of a family of NMDA receptors, it will be important to determine whether discrete subtypes of NMDA receptors are differentially affected in AD (33, 47, 48) . The discrete subtypes of the NMDAR2 genes and the various splice variants of the NMDAR1 gene have different sensitivities to glycine (33, 47, 65) . Furthermore, recent in situ hybridization data would suggest that the different NMDAR2 genes and the different splice variants of the NMDAR l gene have unique distributions in brain (47, 63) . Perhaps cells that preferentially express one or the other of these subtypes are particularly vulnerable to the pathology of AD. With the new antibodies that are becoming available to examine the localization of these subtypes and the in situ hybridization methods for determining their cellular localization, it should be able to address these possibilities in more detail. The previous studies (57, 58, 59, 62) , combined with the results presented here, provide data to support a therapeutic role for glycinergic drugs in AD. It has been suggested that perhaps a partial glycine agonist, a drug which combines the glycine agonist properties to potentially enhance cognition with the glycine antagonist properties to retard disease progression, may actually provide the best solution (24) .
